Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Change in risk of breast cancer after receiving hormone replacement therapy by considering effect-modifiers: a systematic review and dose-response meta-analysis of prospective studies.

Wang K, Li F, Chen L, Lai YM, Zhang X, Li HY.

Oncotarget. 2017 Aug 11;8(46):81109-81124. doi: 10.18632/oncotarget.20154. eCollection 2017 Oct 6.

2.

Schisandrae Fructus Reduces Symptoms of 4-Vinylcyclohexene Diepoxide-Induced Ovarian Failure in Mice.

Shin D, Ha J, Hong SB, Kang GH, Hwang DS, Bae H.

Evid Based Complement Alternat Med. 2017;2017:2564787. doi: 10.1155/2017/2564787. Epub 2017 May 11.

3.

Menopausal hormone therapy: a systematic review of cost-effectiveness evaluations.

Velentzis LS, Salagame U, Canfell K.

BMC Health Serv Res. 2017 May 5;17(1):326. doi: 10.1186/s12913-017-2227-y.

4.

Age-Specific Indicators of a Healthy Lifestyle and Postmenopausal Breast Cancer.

McClain KM, McCullough LE, Bradshaw PT, Shantakumar S, Terry MB, Neugut AI, Gammon MD.

J Womens Health (Larchmt). 2017 Nov;26(11):1176-1184. doi: 10.1089/jwh.2016.6028. Epub 2017 Apr 6.

PMID:
28384095
5.

DNA methylation age is elevated in breast tissue of healthy women.

Sehl ME, Henry JE, Storniolo AM, Ganz PA, Horvath S.

Breast Cancer Res Treat. 2017 Jul;164(1):209-219. doi: 10.1007/s10549-017-4218-4. Epub 2017 Mar 31.

6.

Fibroblast growth factor signalling induces loss of progesterone receptor in breast cancer cells.

Piasecka D, Kitowska K, Czaplinska D, Mieczkowski K, Mieszkowska M, Turczyk L, Skladanowski AC, Zaczek AJ, Biernat W, Kordek R, Romanska HM, Sadej R.

Oncotarget. 2016 Dec 27;7(52):86011-86025. doi: 10.18632/oncotarget.13322.

7.

Menopausal hormone therapy and breast cancer: what is the true size of the increased risk?

Jones ME, Schoemaker MJ, Wright L, McFadden E, Griffin J, Thomas D, Hemming J, Wright K, Ashworth A, Swerdlow AJ.

Br J Cancer. 2016 Aug 23;115(5):607-15. doi: 10.1038/bjc.2016.231. Epub 2016 Jul 28.

8.

Progestin-mediated activation of MAPK and AKT in nuclear progesterone receptor negative breast epithelial cells: The role of membrane progesterone receptors.

Salazar M, Lerma-Ortiz A, Hooks GM, Ashley AK, Ashley RL.

Gene. 2016 Oct 10;591(1):6-13. doi: 10.1016/j.gene.2016.06.044. Epub 2016 Jun 24.

9.

Myeloid thrombomodulin lectin-like domain inhibits osteoclastogenesis and inflammatory bone loss.

Cheng TL, Lai CH, Shieh SJ, Jou YB, Yeh JL, Yang AL, Wang YH, Wang CZ, Chen CH, Shi GY, Ho ML, Wu HL.

Sci Rep. 2016 Jun 17;6:28340. doi: 10.1038/srep28340.

10.

Progesterone receptor membrane component 1 promotes survival of human breast cancer cells and the growth of xenograft tumors.

Clark NC, Friel AM, Pru CA, Zhang L, Shioda T, Rueda BR, Peluso JJ, Pru JK.

Cancer Biol Ther. 2016;17(3):262-71. doi: 10.1080/15384047.2016.1139240. Epub 2016 Jan 19.

11.

Breast cancer incidence and menopausal hormone therapy in Norway from 2004 to 2009: a register-based cohort study.

Suhrke P, Zahl PH.

Cancer Med. 2015 Aug;4(8):1303-8. doi: 10.1002/cam4.474. Epub 2015 May 20.

12.

Menopausal hormone therapy and breast cancer mortality: clinical implications.

Chlebowski RT, Anderson GL.

Ther Adv Drug Saf. 2015 Apr;6(2):45-56. doi: 10.1177/2042098614568300. Review.

13.

Navigating the road ahead: addressing challenges for use of metabolomics in epidemiology studies.

Haznadar M, Maruvada P, Mette E, Milner J, Moore SC, Nicastro HL, Sampson JN, Su LJ, Verma M, Zanetti KA.

Metabolomics. 2014 Apr 1;10(2):176-178.

14.

Optimal cutoffs of obesity measures in relation to cancer risk in postmenopausal women in the Women's Health Initiative Study.

Heo M, Kabat GC, Strickler HD, Lin J, Hou L, Stefanick ML, Anderson GL, Rohan TE.

J Womens Health (Larchmt). 2015 Mar;24(3):218-27. doi: 10.1089/jwh.2014.4977. Epub 2015 Jan 14.

15.

Hormone metabolism pathway genes and mammographic density change after quitting estrogen and progestin combined hormone therapy in the California Teachers Study.

Lee E, Luo J, Su YC, Lewinger JP, Schumacher FR, Van Den Berg D, Wu AH, Bernstein L, Ursin G.

Breast Cancer Res. 2014 Dec 11;16(6):477. doi: 10.1186/s13058-014-0477-8.

16.

Novel daidzein analogs enhance osteogenic activity of bone marrow-derived mesenchymal stem cells and adipose-derived stromal/stem cells through estrogen receptor dependent and independent mechanisms.

Strong AL, Ohlstein JF, Jiang Q, Zhang Q, Zheng S, Boue SM, Elliott S, Gimble JM, Burow ME, Wang G, Bunnell BA.

Stem Cell Res Ther. 2014 Aug 28;5(4):105. doi: 10.1186/scrt493.

17.

Coronary artery disease in women: an unsolved dilemma.

Aziz F.

J Clin Med Res. 2014 Apr;6(2):86-90. doi: 10.14740/jocmr1725w. Epub 2014 Feb 6. Review.

18.

Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers.

Loud JT, Gierach GL, Veenstra TD, Falk RT, Nichols K, Guttmann A, Xu X, Greene MH, Gail MH.

Breast Cancer Res Treat. 2014 Feb;143(3):517-29. doi: 10.1007/s10549-013-2821-6. Epub 2014 Jan 18.

19.

Adiposity, inflammation, genetic variants and risk of post-menopausal breast cancer findings from a prospective-specimen-collection, retrospective-blinded-evaluation (PRoBE) design approach.

Yan XS, Barnholtz-Sloan J, Chu X, Li L, Colonie R, Webster J, Smelser D, Patel N, Prichard J, Stark A.

Springerplus. 2013 Nov 27;2:638. doi: 10.1186/2193-1801-2-638. eCollection 2013.

20.

Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density.

Hou N, Hong S, Wang W, Olopade OI, Dignam JJ, Huo D.

J Natl Cancer Inst. 2013 Sep 18;105(18):1365-72. doi: 10.1093/jnci/djt207. Epub 2013 Sep 3.

Supplemental Content

Support Center